June 27 (Reuters) - Mayne Pharma Group Ltd (MYX) :
- MYX announces acquisition of US generic product portfolio (MYX)
- Deal for US$652M
- Acquisition price represents less than 6 times projected FY 2017 EBITDA
- Acquired portfolio is expected to contribute sales of US$237M in FY 2017 with
gross margins greater than 50%
- Expected to be very significantly accretive to reported and cash earnings per
share in FY 2017
- Will fund the acquisition via an extension of its existing debt facility
- Says entered into an agreement to acquire 37 approved and 5 FDA filed
products from Teva Pharmaceutical Industries Limited
- Will fund acquisition via fully underwritten A$601M 1-for-1.725 accelerated
non-renounceable entitlement offer and A$287M placement
- Entered into a binding agreement to acquire a portfolio of US generic
products from Teva and Allergan
- Shares offered under entitlement offer will be issued at a price of A$1.28
per new share, representing a 9.2% discount
- Forums
- ASX - By Stock
- News: MYX Mayne Pharma acquires US generic product portfolio from Teva and Allergan
June 27 (Reuters) - Mayne Pharma Group Ltd (MYX) : MYX...
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$4.36 |
Change
-0.160(3.54%) |
Mkt cap ! $370.9M |
Open | High | Low | Value | Volume |
$4.51 | $4.51 | $4.32 | $562.8K | 128.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2150 | $4.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.39 | 474 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2150 | 4.350 |
2 | 1134 | 4.340 |
3 | 619 | 4.330 |
2 | 608 | 4.320 |
2 | 608 | 4.310 |
Price($) | Vol. | No. |
---|---|---|
4.390 | 474 | 1 |
4.400 | 474 | 1 |
4.410 | 474 | 1 |
4.420 | 474 | 1 |
4.440 | 9421 | 6 |
Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |